Metal chelation as a potential therapy for Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 920, Issue , 2000, Pages 292-304

  Cuajungco, Math P ^a   Fagét, Kyle Y ^b   Huang, Xudong ^b   Tanzi, Rudolph E ^a   Bush, Ashley I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BLEOMYCIN; CALCIMYCIN; CHELATING AGENT; CHOLINESTERASE INHIBITOR; COPPER; CYCLOHEXANEDIAMINETETRAACETIC ACID; DISULFIRAM; ETHAMBUTOL; IBUPROFEN; INDOMETACIN; IRON; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PENICILLAMINE; PENTETIC ACID; PHENYTOIN; PRESENILIN 1; PRESENILIN 2; PYRITHIONE; THALIDOMIDE; THIOCTIC ACID; TRIENTINE; VALPROIC ACID; ZINC;

ALZHEIMER DISEASE; ANIMAL TISSUE; CHELATION THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; METAL BINDING; MOUSE; NEOCORTEX; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; RISK FACTOR;

ANIMALIA;

EID: 0034527983     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06938.x     Document Type: Conference Paper

References (79)

1. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
2. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene
3. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
4. A familial Alzheimer's disease locus on chromosome 1
5. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease
6. Alpha-2 macroglobulin is genetically associated with Alzheimer's disease
7. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
8. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
9. Sequence of deposition of heterogeneous amyloid beta-peptides and apoE in Down syndrome: Implications for initial events in amyloid plaque formation
10. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
11. Zinc metabolism in the brain: Relevance to human neurodegenerative disorders
12. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease
13. Oxygen toxicity, oxygen radicals, transition metals and disease
14. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease
15. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
16. Most amyloid plaques contain ferritin-rich cells
17. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals
18. Copper, iron and zinc in Alzheimer's disease senile plaques
19. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides
20. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations
21. 2- macroglobulin receptor/low-density lipoprotein receptor-related protein
22. 2-macroglobulin complex
23. 2-macroglobulin attenuates β-amyloid peptide 1-40 fibril formation and associated neurotoxicity in cultured fetal rat cortical neurons
24. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers
25. The role of iron in beta amyloid toxicity
26. Cu(II) potentiation of Alzheimer's Aβ neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction
27. Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione
28. A novel zinc(II) binding site modulates the function of the βA4 amyloid protein precursor of Alzheimer's disease
29. Rapid induction of Alzheimer Aβ amyloid formation by zinc
30. Modulation of Aβ adhesiveness and secretase site cleavage by zinc
31. The amyloid β-protein precursor and its mammalian homologues: Evidence for a zinc-modulated heparin-binding superfamily
32. Zinc and Alzheimer's disease
33. 1-40 aggregation is mediated by conformational factors
34. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
35. The beta A4 amyloid precursor protein binding to copper
36. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)
37. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide
38. Cysteine 144 is a key residue in the copper reduction by the beta-amyloid precursor protein
39. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease
40. 1-42
41. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
42. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress
43. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides
44. The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain
45. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
46. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
47. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease
48. Hydrogen peroxide mediates amyloid β protein toxicity
49. β-Amyloid toxicity in organotypic hippocampal cultures: Protection by Euk-8, a synthetic catalytic free radical scavenger
50. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
51. Historical background and fundamental concepts
52. The present status of chelating agents in medicine
53. Diverse effects of metal chelating agents on the neuronal cytotoxicity of zinc in the hippocampus
54. The stoichiometry of A23187- and X537A-mediated calcium ion transport across lipid bilayers
55. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
56. The possible origin of free radicals from amyloid β peptides in Alzheimer's disease
57. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
58. Resolubilization of Alzheimer and APP transgenic beta amyloid plaque by copper chelators
59. Intramuscular desferrioxamine in patients with Alzheimer's disease
60. Clinically useful chelators of tripositive elements
61. The effects of disulfiram on equine hepatic alcohol dehydrogenase and its efficiency against alcoholism: Vinegar effect
62. Comparative pharmacology of cyclooxygenase inhibitors on platelet function
63. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
64. Protein oxidation and aging
65. Zinc and Alzheimer's disease: Is there a direct link?
66. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice
67. Histological evidence implicating zinc in Alzheimer's disease
68. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
69. Neurobiology of zinc and zinc-containing neurons
70. Brain tissue accumulates 67copper by two ligand-dependent saturable processes
71. The effects of aspirin, indomethacin and their copper complexes on phospholipase activity and on lipid peroxidation in rat liver microsomes
72. Inhibition of ferrous ion induced oxidation of arachidonic acid by indomethacin
73. The metabolism and pharmacology of d-penicillamine in man
74. Bleomycin pharmacology: Mechanism of action and resistance, and clinical pharmacokinetics
75. In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide
76. Chelating drugs and zinc
77. Alpha-lipoic acid as a biological antioxidant
78. Selenium, zinc, and copper changes with valproic acid: Possible relation to drug side effects
79. Zinc and copper metabolism in phenytoin therapy